Jefferies Reiterates Buy Rating on Silence Therapeutics (SLN): "looks cheap at $175M+ EV"
Tweet Send to a Friend
Jefferies analyst Andrew Tsai reiterated a Buy rating and $25.00 price target on Silence Therapeutics (NASDAQ: SLN)The analyst commented, "In ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
